Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments Centre

Sepsis

Click on the title for more information (where available).

Green C, Dinnes J, Takeda A, Cuthbertson BH. Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom. International Journal of Technology Assessment in Health Care 2006;22(1):1-11.

Green C, Dinnes J, Takeda A, Shepherd J, Hartwell D, Cave C et al. The clinical- and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation. Health Technology Assessment 2005;9(11). 

Green C, Dinnes J, Takeda A, and Davidson P. The clinical and cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis: a systematic review and economic evaluation (oral presentation). Heatlh Technology Assessment International (HTAi). HTAi, June 2004, Krackow, Poland . 2004.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×